Skip to main content
. Author manuscript; available in PMC: 2020 Sep 24.
Published in final edited form as: Eur J Cancer. 2020 Apr 16;131:89–97. doi: 10.1016/j.ejca.2020.02.048

Figure 2:

Figure 2:

RSPO2 rs555008 and progression-free survival among patients with KRAS mutant tumors. A Training cohort: RSPO2 rs555008 and PFS (FIRE-3 FOLFIRI/bevacizumab arm). B Validation cohort: RSPO2 rs555008 and PFS (TRIBE FOLFIRI/bevacizumab arm).